1088994-22-2

Basic information

• Product Name: 5-methyl-2-(pyrimidin-2-yl)benzoic acid
• Synonyms: 5-methyl-2-(pyrimidin-2-yl)benzoic acid;Benzoic acid, 5-methyl-2-(2-pyrimidinyl)-
• CAS NO: 1088994-22-2
• Molecular Formula: C₁₂H₁₀N₂O₂
• Molecular Weight: 214.22
• Mol File: 1088994-22-2.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 316℃
• Flash Point: 145℃
• Appearance: white crystal powder
• Density: 1.260
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 3.70±0.36(Predicted)
• CAS DataBase Reference: 5-methyl-2-(pyrimidin-2-yl)benzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 5-methyl-2-(pyrimidin-2-yl)benzoic acid(1088994-22-2)
• EPA Substance Registry System: 5-methyl-2-(pyrimidin-2-yl)benzoic acid(1088994-22-2)

Safety Data

• Hazardous Substances Data: 1088994-22-2(Hazardous Substances Data)

Usage

General Description

5-methyl-2-(pyrimidin-2-yl)benzoic acid is a chemical compound with the molecular formula C13H10N2O2. It is a derivative of benzoic acid, containing a pyrimidine ring attached to the benzene ring at the 2-position. 5-methyl-2-(pyrimidin-2-yl)benzoic acid is used as a building block for the synthesis of various pharmaceuticals and organic compounds. Its chemical structure makes it suitable for use in drug discovery and development, as well as in the production of dyes and pigments. Additionally, the presence of the methyl group and the pyrimidine ring in its structure may confer specific biological activities, making it a potential candidate for drug design and medicinal chemistry research.

Upstream product

• 1722-12-9 2-chloropyrimidine 
• 6967-82-4 2-bromo-5-methylbenzoic acid 
• 1373917-20-4 5-methyl-2-pyrimidin-2-ylbenzonitrile 
• 42872-83-3 2-bromo-5-methylbenzylnitrile 
• 1088994-18-6 5-methyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid methyl ester 
• 103440-52-4 methyl 2-iodo-5-methylbenzoate 
• 52548-14-8 2-iodoyl-5-methylbenzoic acid 
• 1088994-20-0 5-methyl-2-(pyrimidin-2-yl)benzoic acid methyl ester 

Downstream Products

• 1088991-73-4 MK-6096 
• 1252906-25-4 (1R,4S,6R)-4-({[(1,1-dimethylethyl)(diphenyl)silyl]oxy}methyl)-3-{[5-methyl-2-(2-pyrimidinyl)phenyl]carbonyl}-3-azabicyclo[4.1.0]heptane 
• 1252907-92-8 (1S,4S,6S)-3-{[5-methyl-2-(2-pyrimidinyl)phenyl]carbonyl}-4-({[4-(trifluoromethyl)-2-pyridinyl]oxy}methyl)-3-azabicyclo[4.1.0]heptane 
• 1260527-48-7 (+/-)-(5-((5-chloropyridin-2-ylamino)methyl)-6-azaspiro[2.5]octan-6-yl)(5-methyl-2-(pyrimidin-2-yl)phenyl)methanone 
• 1262395-09-4 (S)-(5-(((5-chloropyridin-2-yl)amino)methyl)-6-azaspiro[2.5]octan-6-yl)(5-methyl-2-(pyrimidin-2-yl)phenyl)methanone 
• 1262396-05-3 (6(S)-(((5-chloropyridin-2-yl)amino)methyl)-5-azaspiro[2.4]heptan-5-yl)(5-methyl-2-(pyrimidin-2-yl)phenyl)methanone 
• 1295516-46-9 (1R,6S)-[8-(4,6-dimethyl-pyrimidin-2-yl)-3,8-diaza-bicyclo[4.2.0]oct-3-yl]-(5-methyl-2-pyrimidin-2-yl-phenyl)-methanone 
• 1384261-53-3 (1R,4R,6R)-3-{[5-methyl-2-(2-pyrimidinyl)phenyl]carbonyl}-4-{2-[5-(trifluoromethyl)-2-pyridinyl]ethyl}-3-azabicyclo[4.1.0]heptane 
• 1381971-14-7 N-ethyl-N-{2-[3-(5-fluoropyridin-2-yl)-1H-pyrazol-1-yl]ethyl}-5-methyl-2-(pyrimidin-2-yl)benzamide 

Relevant articles and documents

Condition optimization for synthesis of 5-methyl-2(Pyrimidin-2-yl) benzoic acid

Orexin has been emerged as a hot and frontier research theme in the close relationship with sleep-wake regulation. In this paper, we report a synthetic method for the preparation of 5-methyl-2-(pyrimidin-2-yl)benzoic acid, which is an important molecular fragment of orexin Filorexant (MK-6096). Compared to the previously reported methods, the current route has the advantages of a short synthetic pathway, simple post-treatment, and high yield that provide an effective new methodology for the synthesis of the target compound. Using 2-bromo-5-methyl benzoic acid and 2-chloropyrimidine as raw materials, PdCl2(PPh3)2 is used as a metal catalyst to mediate one-pot genera-tion of 5-methyl-2-(pyrimidin-2-yl)benzoic acid using the Negishi cross-coupling method. The optimum condition involves 2-bromo-5-methylbenzoic acid (10.00 g) and anhydrous zinc chloride powder (6.32 g) together with the catalyst: 2-bromo-5-methylbenzoic acid molar ratio of 0.02 and 2-chloropyrimidine: 2-bromo-5-methylbenzoic acid molar ratio of 1.1:1 at a reaction temperature of 55°C for 14 h. Under these optimum reaction conditions, the maximum yield of 78.4% is attained for 5-methyl-2-(pyrimidin-2-yl) benzoic acid.

SUBSTITUTED 2-AZABICYCLO[3.1.1]HEPTANE AND 2-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS

There is provided a compound of formula (I), wherein L1 to L3, R1 to R4, X, A and B have meanings given in the description, and pharmaceutically acceptable salts, solvates and prodrugs thereof, which compounds are useful as antagonists of the orexin-1 and orexin-2 receptors or as selective antagonists of the orexin-1 receptor, and thus, in particular, in the treatment or prevention of inter alia substance dependence, addiction, anxiety disorders, panic disorders, binge eating, compulsive disorders, impulse control disorders, cognitive impairment and Alzheimer's disease.

USE OF BENZIMIDAZOLE-PROLINE DERIVATIVES

The present invention relates to compounds of the formula (I), wherein Ar1 and Ar2 are as described in the description and to their use as pharmaceuticals for the treatment of sundown syndrome. The invention also relates to the preparation of such compounds and of pharmaceutically acceptable salts thereof.